Research Progress on Anti-PD-1 and PD-L1 Immunotherapy for Gastric Cancer

Abstract

Gastric cancer (GC) is a globally prevalent disease that poses a significant threat to human health and quality of life. With advancing research on tumor immune evasion mechanisms, programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been demonstrated to interact with the tumor microenvironment and mediate tumor immune evasion. This article reviews the latest research progress in this field, explores their expression in gastric cancer, and discusses the therapeutic effects and prospects of targeted drugs, aiming to provide insights for personalized and precision medicine strategies. These efforts seek to reduce patient recurrence and metastasis risks while improving clinical outcomes.